Updates: Office of Infectious Disease and HIV/AIDS Policy
Office of Infectious Disease and HIV/AIDS Policy (OIDP)

- Provides strategic leadership and management among federal agencies and stakeholders to reduce burden of infectious diseases
- Ending the HIV Epidemic; Minority HIV/AIDS Fund; Ready, Set, PrEP
- National Strategic Plans – HIV, Vaccine, STI, Viral Hepatitis, Vectorborne Disease
- Federal Interagency Workgroups
- Federal Advisory Committees
  - Presidential Advisory Council on HIV/AIDS
  - National Vaccine Advisory Committee
  - Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria
  - Advisory Committee on Blood and Tissue Safety and Availability,
  - Tick-Borne Disease Working Group
OIDP Updates

• “Catch Up to Get Ahead” Initiative
  ▪ Redoubles catch-up vaccination efforts for children during August “National Immunization Awareness Month”

• Public Readiness and Emergency Preparedness (PREP) Act
  ▪ Authorizes pharmacists to administer vaccines to children age 3–18 years during emergency declaration
  ▪ Extends immunity to claims for loss per 42 U.S.C. § 247d-6d(a)(1)

• National Vaccine Advisory Committee
  ▪ Last meeting June 9, next meeting Sep 23–24
  ▪ To reconvene Vaccine Confidence and Immunization Equity Subcommittees

• National Vaccine Plan
  ▪ Updates 2010 plan, 5-year horizon
  ▪ Incorporates expert and stakeholder interviews, public comments, interagency reviews
  ▪ Plan for release Dec 2020
Healthy People 2030

• Launched Aug 19, 2020
• 365 core, 144 developmental objectives
• Core objectives
  ▪ Reduce children with no vaccines by age 2y
  ▪ Maintain 1 dose MMR by age 2y
  ▪ Maintain 2 doses MMR by kindergarten
  ▪ Increase 4 doses DTaP by age 2y
  ▪ Increase adolescents who get HPV vaccines
  ▪ Increase people who get flu vaccine every year (leading health indicator)
• Developmental objectives
  ▪ Increase pregnant women who get Tdap
  ▪ Increase people with vaccination records in vaccine registries
  ▪ Increase adults age ≥19y who get recommended vaccinations
Vaccine Safety Report

• **Purpose**
  - Assess evidence on safety of routinely recommended vaccines with review of adverse events reported in literature since last published report in July 2014

• **Evidence review of vaccine safety**
  - Clinical trials, post-marketing surveillance, nationwide reporting systems
  - Builds on prior report using PubMed, EMBASE, NINAHL, CENTRAL, Web of Science, Scopus, TOXLINE
  - New formulations, new indications
  - Types and severity with individual and combination vaccines
  - Transient vs. permanent health risks, frequency and likelihood of adverse events
  - Associated factors (e.g., age, sex, race/ethnicity, comorbidities)

• **Scope of review**
  - FDA-licensed vaccines on CDC-recommended immunization schedules
  - Children, adults, pregnant women
Citations identified in research databases
N = 48,943 (28,704 new)

Hand search, Reference mining, Scientific Information Packets, SEADS, Peer Review and Public Comment
N = 633 (340 new)

Total number of citations reviewed
N = 49,576 (29,044 new)

Citation excludes
(not empirical study or systematic review, not relevant vaccines)
N = 42,691 (25,426 new)

Total titles identified for full text review
N = 6,885 (3,617 new)

Background
(to cite, for reference mining, ongoing trials to watch)
N = 837 (394 new)

Publications excluded based on full text review
N = 5,610 (2,962 new)
Exclude-Participants: n = 151
Exclude-Intervention: n = 1,371
Exclude-Comparator: n = 389
Exclude-Outcome: n = 914
Exclude-Study Design: n = 1,677
Exclude-Language: n = 27
Exclude-Publication year: n = 1,49
Exclude-Publication type: n = 231
Exclude-Duplicate: n = 491

N = 379 included studies reported in 438 publications (278 new)
Vaccine Safety Report – Pending Actions

• Draft report and internal review
• Report presentation and peer-review
• Submit for HHS clearance
• Distribution of finalized report – December 2020